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Abstract
The aim of the present study was to investigate the antibiotic susceptibility patterns and molecular epidemiology of clinical methicil-
lin-resistant Staphylococcus aureus (MRSA) isolates recovered in 24 hospitals in 20 cities in Croatia from October to December 2004.
A total of 1815 consecutive S. aureus isolates were recovered, 248 of which were MRSA. The MRSA isolates were analysed using
spa typing, multilocus sequence typing and SCCmec typing. Furthermore, the presence of Panton–Valentine leukocidin (PVL) genes
was determined as a genetic marker for community-associated MRSA. The MRSA prevalence was 14%. Ninety-six per cent of the
MRSA isolates were resistant to ciproﬂoxacin, 95% to clindamycin and azithromycin, 94% to gentamicin, and 93% to erythromycin.
The majority of the MRSA isolates (78%) was associated with the ST111-MRSA-I clone. In addition, various other endemic MRSA
clones were observed, such as the ST247-MRSA-I (4%), the ST45-MRSA-IV (2%), the ST5-MRSA-I (2%), the ST239-MRSA-III (2%),
the ST5-MRSA-II (1%), the ST8-MRSA-IV (1%) and the ST5-MRSA-IV (<1%) clones. Furthermore, we observed one PVL-negative
ST80-MRSA-IV isolate. Four PVL-positive MRSA isolates were found, associated with ST8-MRSA-IV, ST80-MRSA-IV and ST80-MRSA-I.
The ST111-MRSA-I clone was predominant in Croatia. Future surveillance studies of MRSA are important to elucidate whether
changes in the clonal distribution of MRSA will occur, and if the minor endemic MRSA clones observed in the present study will
replace the ST111-MRSA-I clone on a large scale.
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Introduction
Methicillin-resistant Staphylococcus aureus (MRSA) is one of
the most signiﬁcant hospital-associated (HA) pathogens, caus-
ing a wide range of infections. The ﬁrst report on MRSA
appeared in 1960, and, since then, various HA-MRSA clones
have disseminated worldwide [1]. The prevalence of MRSA
bacteraemia varies from 1% in Norway to 67% in Japan [1,2].
In addition to HA infections, MRSA causes community-asso-
ciated (CA) infections, especially skin and soft tissue infections
and necrotizing pneumonia. The increased rate of CA-MRSA
infections is a public health concern, and a challenge for infec-
tion control, as MRSA is observed in nursing homes, kindergar-
tens and schools. However, studies on CA-MRSA prevalence
are rare. HA-MRSA and CA-MRSA can be distinguished on the
basis of a combination of the genetic background, the staphylo-
coccal cassette chromosome mec (SCCmec) and the presence
of Panton-Valentine leukocidin (PVL) [1].
Strategies to control the transmission of MRSA require
knowledge about the prevalence, nature and number of MRSA
clones [3]. In Croatia, antibiotic resistance surveillance studies
for relevant clinical bacteria are performed and the results
are published yearly (http://www.amzh.hr/eng/index-eng.htm).
However, only limited information on the nationwide spread
of MRSA clones in Croatian hospitals is available [4].
The aim of the present study was to investigate the preva-
lence and the molecular epidemiology of MRSA isolated from
ambulatory and hospitalized patients in Croatia during a 3-
month period in 2004, using SCCmec typing, multilocus
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sequence typing (MLST) and spa typing. PVL was detected as
a marker for CA-MRSA [5].
Materials and Methods
Clinical isolates
From October to December 2004, 24 hospitals, with 104–
1724 beds (mean 490 beds), in 20 Croatian cities collected
1815 consecutive clinical S. aureus isolates, ranging from six
to 224 (mean 56) isolates per hospital. One isolate per
patient was included in the study. The isolates were sent to
the Clinical Hospital Centre Zagreb, Croatia for molecular
analyses. All MRSA isolates were sent to the Maastricht Uni-
versity Medical Centre, The Netherlands, for spa typing.
Antimicrobial susceptibility testing
Susceptibility testing was performed according to the guide-
lines of the CLSI [6], using the microbroth dilution method
for the following antibiotics: penicillin, oxacillin, cefoxitin,
erythromycin, clindamycin, azithromycin, gentamicin, amika-
cin, tetracycline, rifampicin, trimethoprim–sulphamethoxaz-
ole, linezolid, ciproﬂoxacin and vancomycin. Susceptibility
testing for fusidic acid and mupirocin was performed accord-
ing to the guidelines of the French Society of Microbiology,
using the disk diffusion method [7]. The oxacillin-resistant
isolates were tested for the presence of the mecA gene [8].
SCCmec typing
SCCmec typing was performed using the multiplex PCR
described by Oliveira et al. [9]. In addition, ccr typing was
performed according to the method of Ito et al. [10,11],
using modiﬁed primer b2 [12].
Typing of the spa locus
Real-time ampliﬁcation of the spa locus, followed by
sequencing of the short sequence repeat region, was per-
formed as described previously [13]. The spa types were
clustered into spa clonal complexes (CCs), using the algo-
rithm based upon repeat pattern (BURP) with Ridom Staph-
Type 1.4 software (http://www.ridom.de). As it has been
shown that spa typing/BURP data are in accordance with
results obtained using MLST and pulsed-ﬁeld gel electro-
phoresis, the putative MLST CC was allocated through the
Ridom SpaServer (http://spaserver.ridom.de) [14,15].
MLST analyses
To conﬁrm the association between MLST and spa typing/
BURP results, MLST was performed for representative iso-
lates of each major spa type [12,16].
Detection of PVL
The detection of the genes coding for PVL was performed as
described previously by Lina et al. [17].
Results
MRSA prevalence
During the 3-month study period, 248 MRSA isolates were
recovered, giving a prevalence of 14%. The MRSA isolates
were from various body sites, i.e. 109 (44%) from wound
infections, 39 (16%) from tracheal aspirates, 14 (6%) from
nasal swabs, 13 (5%) from bloodstream infections, 12 (5%)
from urinary tract infections, ten (4%) from central venous
catheters and 51 (21%) from various other body sites. The
MRSA prevalence varied among hospitals, from 2% in Split to
95% in Zagreb. In the three small county hospitals of Cˇako-
vec, Nasice and Ogulin (117, 150 and 351 beds, respectively)
and the Clinical Hospital Centre Rijeka (a 1191-bed tertiary-
care hospital), no MRSA isolate was detected during the
study. The MRSA prevalence was related neither to the
number of beds per hospital, nor to a speciﬁc geographical
area, nor to hospital infection control policy, nor to the
patient population. The absence of wards for orthopaedic,
plastic, cardiac and vascular surgery could contribute to the
low MRSA prevalence in the latter four hospitals.
Antimicrobial susceptibility patterns
All MRSA isolates were resistant to the b-lactam antibiotics
tested, i.e. penicillin, oxacillin and cefoxitin, and all isolates
were susceptible to linezolid and vancomycin. Ninety-six
per cent of the MRSA isolates were resistant to ciproﬂoxa-
cin, 95% to clindamycin and azithromycin, 94% to gentamicin,
93% to erythromycin, 10% to rifampicin, 9% to mupirocin
and to tetracycline, 8% to amikacin, 3% to trimethoprim–
sulphamethoxazole and 0.4% to fusidic acid.
Distribution of SCCmec elements
The most prevalent SCCmec element was type I (n = 224;
90%), followed by SCCmec type IV (n = 15; 6%), SCCmec
type II (n = 5; 2%) and SCCmec type III (n = 4; 2%). Six of the
SCCmec elements, four SCCmec type IV and two SCCmec
type III, could not be typed with the method of Oliveira et al.
[9] but could be typed with the method of Ito et al. [10].
The four non-typeable SCCmec type IV elements all har-
boured ccrAB2, and lacked mecI and the dcs region. However,
one element harboured the pls region, which is characteristic
for SCCmec type I, and another harboured locus F, which is
characteristic for SCCmec type III. The two non-typeable
SCCmec type III elements harboured mecA and loci C, D, E
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and F. Therefore, they differ from SCCmec type III with
regard to the presence of locus D, the dcs region.
Distribution of spa CCs and MLST analyses
Thirty-one spa types were found among the 248 MRSA
isolates, and were grouped into four spa CCs and eight
singletons. Two isolates could not be spa typed (Table 1).
One main spa CC, spa CC 041, comprising 82% of the iso-
lates, was associated with MLST CC5. Within MLST CC5,
13 new spa types were found (Table 1). The distribution of
the spa types among spa CC 041 is presented in Table 2. In
addition, three spa CCs with no founder, associated with
MLST CC45, CC239 and CC8, were observed, accounting
for 4%, 2% and 9% of the isolates, respectively (Table 1). Of
the eight isolates that were classiﬁed as singletons, two were
associated with MLST CC1 and four with MLST CC80.
MLST analyses conﬁrmed the association between spa CC
and MLST CC (Table 1).
Distribution of MRSA clones
The combination of the genetic background and SCCmec
was used to deﬁne the MRSA clones in Croatia [16]. The
majority of the MRSA isolates (n = 193; 78%) were associ-
ated with a single-locus variant (ST111-MRSA-I) of the
Southern German (ST228-MRSA-I) clone. Other MRSA
clones observed were the Iberian (ST247-MRSA-I) clone
(n = 11; 4%), the Berlin (ST45-MRSA-IV) clone (n = 5; 2%),
the UK EMRSA-3 (ST5-MRSA-I) clone (n = 5; 2%), the Brazil-
ian/Hungarian (ST239-MRSA-III) clone (n = 4; 2%), the New
York/Japan (ST5-MRSA-Ii) clone (n = 3; 1%), the UK EMRSA-
2/-6 (ST8-MRSA-IV) clone (n = 3; 1%) and the Paediatric
(ST5-MRSA-IV) clone (n = 1; <1%). Figure 1 shows the distri-
bution of the MRSA clones in Croatia.
Nine isolates could not be associated with endemic MRSA
clones: four isolates (2%), observed in Pula, Split and Vukovar,
were associated with ST45-MRSA-I, and single isolates were
associated with ST1-MRSA-I, ST1-MRSA-IV, ST228-MRSA-II,
ST239-MRSA-I and ST80-MRSA-IV. The PVL-negative ST80-
MRSA-IV isolate did not harbour collagen adhesion or toxic
shock syndrome toxin-1 [4]. Six isolates harbouring SCCmec
type I and associated with MLST CC8 (spa type t008) could
not be associated with a particular MRSA clone, but they were
most likely associated with the Archaic or the Iberian clone.
Four of the 248 MRSA isolates could not be related to an
MRSA clone, either because the spa type was not related to an
MRSA clone, or because they could not be spa typed.
Prevalence of PVL and distribution of CA-MRSA clones
Four of the 248 MRSA isolates (1.6%) harboured PVL; three
of these harboured SCCmec type IV, and the other har-
boured SCCmec type I. These isolates had a genetic back-
ground associated with CA-MRSA. One isolate had spa
type t008, associated with MLST CC8, and three isolates had
spa type t044, associated with MLST CC80. Of the four
PVL-positive MRSA isolates, one was from the Dubrovnik
area and associated with ST8-MRSA-IV, two were from the
Split and Zadar area and associated with the ST80-MRSA-IV
(European CA-MRSA) clone, and one was from Bjelovar and
associated with ST80-MRSA-I.
Discussion
To control the MRSA transmission in and among hospitals, it
is important to study the prevalence, nature and number
of MRSA clones present. This study was performed to
TABLE 1. Composition of the spa
clonal complexes (CC)s spa CC
No. (%) of
isolates
No. (%) of
spa types spa typesa STb Putative CC
spa CCc 041 203 (82) 21 (68) t001, t003, t041, t811, t892, t1003,
t1185, t2521, t2625, t2687, t2688,
t2692, t2746, t2766, t2822, t2823,
t2824, t2825, t2827, t2836, t2837
111, 1410d 5
No founder 2 9 (4) 2 (6) t015, t2682 45 45
No founder 3 5 (2) 2 (6) t030, t037 239
No founder 4 21 (8) 2 (6) t008, t051 8, 247e 8
Singletons 8 (3) 4 (13) t044, t127, t1605, t2608 80 1, 80f
NT 2 (1)
Total 248 (100) 31 (100)
MLST, multilocus sequence typing; NT, not typeable; ST, sequence type.
aBold type indicates spa types for which MLST analysis was performed. The new spa types are underlined.
bAs determined with MLST.
cAs determined with MLST and eBURST.
dTwo isolates spa typed as t003 and t041 had ST111, a single-locus variant of ST228, at the pta locus. A second iso-
late spa typed as t041 had ST1410 (MLST proﬁle 1-4-1-8-46-24-29), a double-locus variant of ST228, at the gmk locus
and pta locus.
eOne isolate spa typed as t008 had ST8, and one isolate spa typed as t051 had ST247.
fspa type t044 is associated with CC80, and spa type t127 is associated with CC1.
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investigate the antibiotic susceptibility patterns and the popu-
lation structure of MRSA in Croatia. The majority of the
MRSA isolates were associated with a variant of the South-
ern German clone. Furthermore, MRSA isolates associated
with the Berlin, UK EMRSA-3, Brazilian/Hungarian, New
York/Japan, UK EMRSA-2/-6 and Paediatric clones were
observed. Four PVL-positive MRSA isolates were likewise
identiﬁed.
Enright et al. [16] proposed that the combination of the
genetic background and SCCmec type should be used to
describe MRSA clones. Typing of the spa locus has been
shown to be a reliable method for long-term epidemiological
studies, and spa typing/BURP data are in accordance with
results obtained by MLST. Nevertheless, spa typing should
preferably be used in combination with additional genetic
markers, e.g. SCCmec [1].
The difference between the MRSA prevalence observed
in this study (14%) and that of 37% previously observed [2]
might be due to differences in the origin of the isolates, i.e.
clinical isolates from various sources rather than blood-
stream isolates. When the antibiotic susceptibility pattern of
the MRSA isolates of this study (October to December
2004) was compared with that of isolates from between
1999 and 2003, there were increases in the levels of
resistance to most antibiotics, i.e. azithromycin (64–95%),
ciproﬂoxacin (57–96%), clindamycin (49–95%), gentamicin
(65–94%) and muprirocin (7–12%), whereas the rifampicin
resistance level decreased (from 50% in 1999 to 11% in
2003). The fusidic acid resistance level decreased from
1999 to 2001 (from 5.3% to 2%), increased between 2002
and 2003 (from 2% to 6%) and decreased to 0.4% in 2004
(http://www.amzh.hr/eng/index-eng.htm). The data on antibi-
otic susceptibility were consistent with data from a previous
study on MRSA bloodstream isolates, showing that the vast
majority of MRSA isolates in Croatia were multiresistant
and belonged to ST111-MRSA-I, a single-locus variant of
ST228-MRSA-I (Southern German clone) [4]. Until 1995,
multiresistance of MRSA strains associated with ST228-
Varaždin
Čakovec
Koprivnica
Zagreb Bjelovar
Virovitica
Osijek
Nasice
Nova Gradiška
Slavonski Brod
Zadar
Split
Dubrovnik
ST5-MRSA-I
ST5-MRSA-II
ST5-MRSA-IV
ST8-MRSA-IV
ST45-MRSA-IV
ST111-MRSA-I
ST239-MRSA-III
ST247-MTSA-I
Vinkovci
VukovarSisak
Karlovac
Ogulin
Rijeka
Pula
FIG. 1. Map of Croatia showing the distribu-
tion of the endemic methicillin-resistant Staph-
ylococcus aureus (MRSA) clones.
TABLE 2. Composition of spa clonal complex (CC) 041
spa type No. (%) of isolates
t001 34 (17)
t003 7 (3)
t041 117 (58)
t811 1 (0.5)
t892 9 (4)
t1003 3 (1)
t1185 1 (0.5)
t2521 1 (0.5)
t2625 1 (0.5)
t2687 1 (0.5)
t2688 13 (6)
t2692 4 (2)
t2746 2 (1)
t2766 1 (0.5)
t2822 2 (1)
t2823 1 (0.5)
t2824 1 (0.5)
t2825 1 (0.5)
t2827 1 (0.5)
t2836 1 (0.5)
t2837 1 (0.5)
Total 203 (100)
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MRSA-I had been observed in various countries. Nonethe-
less, recent ST228-MRSA-I isolates in Germany were resis-
tant to both b-lactam antibiotics and one or two antibiotics
[18].
MRSA strains related to the Southern German clone have
been previously observed in Croatia [4], and in the neigh-
bouring countries of Austria, Hungary and Slovenia [1]. In
Hungary, the Southern German clone, together with the
New York/Japan clone, represented 85% of the MRSA iso-
lates between 2001 and 2004 [19]. ST111-MRSA-I was found
in 21 of the 24 Croatian hospitals. The high prevalence of
ST111-MRSA-I is particular to Croatia, as, to the best of our
knowledge, no other study has found such a high prevalence
of ST111-MRSA-I. However, a recent study of MRSA isolates
in France reported the predominance of the Lyon (ST8-
MRSA-IV) clone, which was observed in nearly 70% of the
MRSA isolates [20]. This suggests that ST111-MRSA-I has as
yet undiscovered features that promote its ﬁtness and inter-
action with hosts in Croatia, which may include searching for
an entry site, targeting a place for multiplication in the host,
becoming persistent in the host, and reaching the next host.
It has been observed that individuals with nasal S. aureus col-
onization are at increased risk of developing an S. aureus
infection. Furthermore, S. aureus of any genotype can
become a life-threatening pathogen under favourable circum-
stances, and some clones are more virulent than others [21].
In the past decade, it has been shown that several S. aureus
lineages are highly epidemic [1]. However, whether certain
S. aureus lineages are more able to colonize or to infect
humans is unknown [21].
The Iberian (ST247-MRSA-I) clone, which was the second
most frequent clone in Croatia, has been observed previ-
ously in Croatia as well as in the neighbouring countries of
Austria, the Czech Republic, Hungary and Slovenia [1,4].
Although the Berlin (ST45-MRSA-IV) clone, the UK EMRSA-
3 (ST5-MRSA-I) clone, the Brazilian/Hungarian (ST239-
MRSA-II) clone, the New York/Japan (ST5-MRSA-Ii) clone,
the UK EMRSA-2/-6 (ST8-MRSA-IV) clone, the Paediatric
(ST5-MRSA-IV) clone, the PVL-negative ST1-MRSA-IV clone
and the ST80-MRSA-IV clone have not been observed before
in Croatia [1], these MRSA clones have been reported previ-
ously in the countries neighbouring Croatia. ST45-MRSA-IV
has been observed in Austria and Hungary, ST5-MRSA-I in
Slovenia, ST239-MRSA-III in Austria, the Czech Republic,
Hungary and Slovenia, ST5-MRSA-II in Hungary, ST8-MRSA-
IV in Austria and Hungary, and ST5-MRSA-IV in Austria [1].
PVL-negative ST1-MRSA-IV has been described in Australia
and Portugal [22,23], whereas PVL-negative ST80-MRSA-IV
has not been described previously. The observation that
these minor MRSA clones were observed in the large cities,
such as the capital Zagreb, and those on the coast, such as
Dubrovnik, might suggest that these MRSA clones were
imported from abroad (Fig. 1).
ST45-MRSA-I, ST1-MRSA-I, ST228-MRSA-II and ST239-
MRSA-I were not associated with the major MRSA clones
[1]. The observation of an uncommon SCCmec element in
an uncommon S. aureus lineage can be explained by the
exchange of the SCCmec element through homologous
recombination among MRSA strains [24]. For example,
studies have described ST45-MRSA-I in The Netherlands,
ST45-MRSA-II in Poland, ST45-MRSA-III in Belgium, and
ST45-MRSA-V in Portugal [23,25–27].
CA-MRSA isolates usually harbour SCCmec type IV or
type V, and often PVL genes, but may differ in their genetic
background (CC1, CC8, CC30, CC59 or CC80) [5].
PVL-positive MRSA strains with a heterogeneous genetic
background were observed in Croatia. PVL-positive
ST8-MRSA-IV has been observed previously in countries
neighbouring Croatia, such as Austria and Bulgaria [1],
whereas ST80-MRSA-IV (European CA-MRSA) has been
found before in both Croatia and the neighbouring countries
of Austria, Bulgaria, Romania and Slovenia, as well as in
former Yugoslavia [1]. PVL-positive ST80-MRSA-I has not
been observed previously.
Two non-typeable SCCmec type IV elements lacked
locus D (dcs region) and these could be SCCmec type IVE/F,
previously observed in Ireland [28]. The other two non-type-
able SCCmec type IV elements, one harbouring the pls
region and the other locus F, have, to our knowledge, not
been reported earlier. Two MRSA isolates contained a non-
typeable SCCmec type III element that harboured locus D
(dcs region), which is normally observed in SCCmec types I,
II and IV. Similar SCCmec elements have been observed pre-
viously in Croatia and Portugal [4,29]. These novel SCCmec
elements may have originated through recombination among
existing SCCmec elements [30].
In summary, ST111-MRSA-I is widely disseminated in
Croatia. Furthermore, other MRSA clones, such as ST5-
MRSA-I, ST239-MRSA-III, ST5-MRSA-II, ST8-MRSA-IV and
ST5-MRSA-IV, were observed. Future surveillance studies of
MRSA isolates are important to elucidate whether changes in
the clonal distribution of MRSA will occur in the future and
whether the minor MRSA clones observed in the present
study will replace ST111-MRSA-I.
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